Pzena Investment Management LLC Acquires 599 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Pzena Investment Management LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 22.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,223 shares of the biopharmaceutical company’s stock after acquiring an additional 599 shares during the quarter. Pzena Investment Management LLC’s holdings in Gilead Sciences were worth $298,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. HHM Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership purchased a new position in Gilead Sciences during the fourth quarter valued at $28,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter worth $29,000. Crews Bank & Trust bought a new position in shares of Gilead Sciences during the fourth quarter valued at $31,000. Finally, Stephens Consulting LLC raised its position in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 260 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of analyst reports. Wolfe Research assumed coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They set an “outperform” rating and a $110.00 price objective for the company. Cantor Fitzgerald restated a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a report on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Mizuho boosted their price target on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Finally, The Goldman Sachs Group lifted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $104.52.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $114.43 on Wednesday. The firm has a market cap of $142.50 billion, a price-to-earnings ratio of 309.27, a P/E/G ratio of 0.71 and a beta of 0.21. The firm has a fifty day moving average price of $100.56 and a 200 day moving average price of $92.18. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.76%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio is 854.05%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total value of $260,225.00. Following the completion of the transaction, the chief financial officer now owns 169,061 shares in the company, valued at approximately $17,597,559.49. This trade represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 293,356 shares of company stock worth $29,166,240. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.